Balyasny Asset Management
BMRN icon

Balyasny Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Balyasny Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-6,800
Closed -$560K – 2753
2024
Q2 		$560K Buy
+6,800
New +$566K ﹤0.01% 2021

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Balyasny Asset Management's BMRN Position: Q2 2026 in Review

Balyasny Asset Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 23% in Q2 2026, selling an estimated $16.9M and leaving 1,054,613 shares worth $60.3M. The position accounts for 0.08% of the portfolio, ranked #312.

Balyasny Asset Management first reported a position in BMRN in Q2 2014 and has held it in 42 quarters since. The position peaked at $156M in Q4 2017. 566 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Balyasny Asset Management held 1,054,613 shares of BioMarin Pharmaceuticals worth $60.3M as of Q2 2026.
  • Balyasny Asset Management sold 308,139 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $16.9M.
  • BioMarin Pharmaceuticals made up 0.08% of Balyasny Asset Management's portfolio in Q2 2026, its #312 holding.
  • Balyasny Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2014 and has held it in 42 quarters since.
  • Balyasny Asset Management's BioMarin Pharmaceuticals position peaked at $156M in Q4 2017.
  • 566 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.